Two Shots a Year for Hypertension? How RNA Silencing Could Transform Cardiometabolic Care

Poor medication persistence remains one of the hardest barriers to long-term blood pressure control. For people with diabetes, the stakes are especially high because hypertension adds to cardiovascular and kidney risk. Now, research into RNAi for hypertension in people with diabetes is raising an intriguing possibility: could an injection given only once or twice a year help provide sustained blood pressure control? Zilebesiran, an investigational RNA interference therapy, is testing that concept by targeting angiotensinogen production in the liver. Early and mid-stage results are promising, although important questions about safety, high-risk patients, and long-term outcomes remain.

Table of Contents

• How RNA interference could change hypertension treatment
• What the zilebesiran clinical trials show
• Why RNAi matters for patients with diabetes
• Safety and practical questions clinicians should watch
• FAQs
• Conclusion

How RNAi Hypertension Therapy Targets Angiotensinogen

Traditional hypertension treatment often requires one or more pills taken every day. However, missed doses, treatment fatigue, side effects, cost, and complex medication schedules can weaken blood pressure control over time. For patients already managing glucose, lipids, kidney disease, and other cardiometabolic risks, another daily medication can add to that burden.

Zilebesiran takes a different approach. It is a small interfering RNA, or siRNA, therapy designed to reduce production of angiotensinogen in the liver. Angiotensinogen sits near the beginning of the renin-angiotensin-aldosterone system, a pathway that plays a central role in regulating blood pressure.

Instead of blocking a receptor or enzyme each day, RNA interference reduces production of the target protein itself. Consequently, one injection may produce an effect lasting for months.

An early phase 1 study published in the New England Journal of Medicine found that single doses of zilebesiran produced dose-dependent reductions in serum angiotensinogen and 24-hour ambulatory blood pressure. These effects were sustained for up to 24 weeks.

That durability is what makes RNAi-based hypertension treatment particularly interesting for people with diabetes. Rather than relying entirely on daily medication behavior, clinicians might eventually have another way to provide continuous background blood pressure control.

However, zilebesiran remains investigational. It should not be viewed as a replacement for established hypertension therapy at this stage.

What Zilebesiran Trials Tell Us So Far

Evidence became stronger with the phase 2 KARDIA program. In KARDIA-2, researchers studied 663 randomized patients whose hypertension remained inadequately controlled after a run-in period with indapamide, amlodipine, or olmesartan. Participants then received a single 600-mg injection of zilebesiran or placebo.

At three months, the placebo-adjusted reduction in 24-hour mean ambulatory systolic blood pressure was 12.1 mmHg with indapamide, 9.7 mmHg with amlodipine, and 4.5 mmHg with olmesartan. The differences were statistically significant in all three treatment groups. Moreover, blood pressure effects persisted through six months for many participants. The findings were published in JAMA.

Still, the picture becomes more nuanced in higher-risk patients. KARDIA-3 evaluated zilebesiran as add-on therapy in adults with uncontrolled hypertension and established cardiovascular disease or high cardiovascular risk. In the main cohort, placebo-adjusted office systolic blood pressure reductions at three months were 5.0 mmHg with 300 mg and 3.3 mmHg with 600 mg. However, the primary results did not meet statistical significance after adjustment for multiple comparisons.

That finding matters because these high-risk patients more closely resemble many people seen in diabetes practices. Therefore, the results support continued investigation rather than assumptions that benefits seen in lower-risk populations will automatically translate to every patient.

Why RNAi for Hypertension Could Matter in Diabetes

Hypertension rarely occurs alone in people with type 2 diabetes. Instead, clinicians often manage overlapping risks involving glucose, obesity, chronic kidney disease, dyslipidemia, and cardiovascular disease.

Current diabetes care reflects this broader approach. The American Diabetes Association Standards of Care emphasize comprehensive cardiovascular risk reduction, including appropriate use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes who have cardiovascular or kidney risk.

Blood pressure control remains another central part of that strategy. In fact, many patients require several medications to reach individualized targets, especially when chronic kidney disease is present. Clinicians must also monitor kidney function and potassium when therapies affecting the renin-angiotensin system are used.

For additional clinical context, Diabetes in Control has examined intensive blood pressure management in diabetes and the emerging role of GLP-1 therapies in hypertension.

Against this background, RNAi therapy for hypertension could eventually offer something different for people with diabetes. Its biggest advantage may not simply be another reduction in systolic blood pressure. Instead, long-duration therapy could reduce dependence on perfect day-to-day medication adherence.

For someone taking several medications every morning and evening, replacing even part of that daily burden with infrequent dosing could be meaningful. Nevertheless, clinical outcome data must establish that prolonged angiotensinogen suppression is both safe and beneficial over time.

Safety and Clinical Questions Still Need Answers

Long-lasting activity can be an advantage, but it also creates a clinical challenge. A daily tablet can usually be stopped when hypotension, kidney dysfunction, or electrolyte abnormalities develop. An RNA-based therapy designed to work for months cannot simply be removed after injection.

KARDIA-2 therefore offers important safety signals. Hyperkalemia, hypotension, and acute kidney failure events occurred more often with zilebesiran than placebo, although most episodes were mild and resolved without medical intervention.

Researchers continue to evaluate kidney function, potassium, hypotension, and other potential effects of sustained renin-angiotensin system suppression. These issues are especially relevant in diabetes because chronic kidney disease and multidrug therapy are common.

Clinicians will need clear guidance on patient selection, laboratory monitoring, interactions with ACE inhibitors or ARBs, management during acute illness, and what to do when blood pressure falls too far. In addition, the long duration of RNA interference makes careful selection particularly important because its therapeutic effect cannot be quickly reversed.

Most importantly, reducing blood pressure is not the same as proving fewer heart attacks, strokes, kidney events, or cardiovascular deaths. Larger and longer studies will be needed to establish whether the convenience and pharmacologic durability of RNA interference translate into better clinical outcomes.

FAQs

What is RNA interference therapy for hypertension?

RNA interference uses small RNA molecules to reduce production of a specific protein. Zilebesiran targets liver production of angiotensinogen, an upstream component of the renin-angiotensin system that helps regulate blood pressure.

Is zilebesiran approved for hypertension or diabetes?

No. Zilebesiran remains an investigational treatment. Current evidence supports further clinical development, but it is not established routine therapy for hypertension in people with diabetes.

Could zilebesiran really be given only twice a year?

Clinical studies have shown blood pressure effects lasting as long as six months after a single injection. Therefore, twice-yearly dosing is a potential treatment model being investigated rather than an established prescribing schedule.

Why could RNAi therapy be useful for people with diabetes?

People with diabetes often take multiple medications for glucose, blood pressure, cholesterol, cardiovascular disease, and kidney protection. An infrequently administered hypertension therapy could potentially reduce daily treatment burden while providing sustained blood pressure control.

What are the main safety concerns?

Researchers are watching for hypotension, hyperkalemia, kidney function changes, injection-site reactions, and risks associated with prolonged suppression of the renin-angiotensin system. Long-term cardiovascular and kidney outcome data are also still needed.

Conclusion

The emerging role of RNAi in hypertension treatment represents a potentially important shift in cardiometabolic care. Zilebesiran has demonstrated that silencing hepatic angiotensinogen can lower blood pressure for months after a single injection, while phase 2 studies have provided encouraging evidence for its use alongside established antihypertensive drugs. However, results in higher-risk populations have also shown why enthusiasm should remain measured.

For diabetes clinicians, the concept is compelling because persistent blood pressure control could address both cardiovascular risk and one of medicine’s most stubborn problems: long-term medication persistence. Still, established therapies remain the standard of care while larger studies define safety, appropriate patient selection, and cardiovascular outcomes.

If RNA interference ultimately delivers durable blood pressure reduction with acceptable long-term safety, the future hypertension visit could look very different. Two injections a year may sound futuristic today, but the clinical research needed to test that possibility is already underway.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.